Table 1 Relationship between NAT10 expression levels and clinicopathologic characteristics of GC patients (n = 158)

Age (years)

< 65 (n = 72)

49(68.1)

23(31.9)

0.470

≥ 65 (n = 86)

63(73.3)

23(26.7)

Gender

Male (n = 104)

73(70.2)

31(29.8)

0.079

Female (n = 54)

39(72.2)

15(27.8)

Tumor location

Gastric cardia (n = 14)

11(78.6)

3(21.4)

0.304

Gastric antrum (n = 71)

46(64.8)

25(35.2)

Gastric corpus (n = 73)

55(75.3)

18(24.7)

Tumor size

< 2 (n = 27)

21(77.8)

6(22.2)

0.523

2–5 (n = 56)

37(66.1)

19(33.9)

> 5 (n = 75)

54(72.0)

21(28.0)

T stage

T1, T2 (n = 20)

16(80.0)

4(20.0)

0.033^*

T3, T4 (n = 138)

96(69.6)

42(30.4)

N stage

N0, N1 (n = 77)

57(74.0)

20(26.0)

0.397

N2, N3 (n = 81)

55(67.9)

26(32.1)

M stage

M0 (n = 153)

108(70.6)

45(29.4)

0.648

M1 (n = 5)

4(80.0)

1(20.0)

UICC stages

Stage I, II (n = 53)

41(77.4)

12(22.6)

0.023^*

Stage III, IV (n = 105)

71(67.6)

34(32.4)

Differentiation

Well/Moderate (n = 54)

42(77.8)

12(22.2)

0.169

Poor (n = 104)

70(67.3)

34(32.7)